Drugs / KT032
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07420010 | Mar 2026 → Dec 2028 expected | colorectal cancer, mesothelioma, ovarian cancer | Weijia Fang, MD | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KT032 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07420010 ↗ |
| Modality | Cell therapy | “CAR-T cells/kg” NCT07420010 ↗ |
| Target | MSLN | “anti-MSLN chimeric antigen receptor autologous T cell injection” NCT07420010 ↗ |